MedTrace Logo

A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone

NCT00880841 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2017-06-23

No results posted yet for this study

Summary

A single-dose pilot study of an investigational capsule formulation of 2 mg/.05 mg Buprenorphine/Naloxone.

NIDA Contract No. HHSN271200577414C

Conditions

  • Healthy

Interventions

DRUG

Buprenorphine / Naloxone

oral formulation of buprenorphine / naloxone

Sponsors & Collaborators

  • NanoSHIFT LLC

    lead INDUSTRY

Principal Investigators

  • Mark Leibowitz, MD · CEDRA Clinical Research

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00880841 on ClinicalTrials.gov